New antiarrhythmic targets to control intracellular calcium handling

Area of Science:

• Cardiology
• Pharmacology
• Molecular Biology

Background:

• Sudden cardiac death (SCD) from ventricular arrhythmias remains a significant clinical challenge.
• Current drug therapies for preventing SCD offer limited efficacy, necessitating novel therapeutic strategies.
• Intracellular calcium (Ca2+) handling is a critical determinant of cardiac electrical stability.

Purpose of the Study:

• To review emerging antiarrhythmic drug targets involved in intracellular calcium regulation.
• To evaluate the potential of novel drugs targeting CaMKII, NCX, RyR/Calstabin, and INa-Late.
• To assess the clinical applicability of these new antiarrhythmic agents.

Main Methods:

• Literature review of preclinical and clinical studies on novel antiarrhythmic drugs.
• Evaluation of drugs targeting Ca(2+)/Calmodulin-dependent protein kinase II (CaMKII).
• Assessment of drugs affecting the Na/Ca exchanger (NCX), Ryanodine receptor (RyR), and late sodium current (INa-Late).

Main Results:

• Several novel drug candidates (SEA-0400, K201, KN-93, W7, ranolazine, sophocarpine, GS-967) show potential by modulating key calcium handling targets.
• These targets, including CaMKII, NCX, RyR, and INa-Late, are implicated in the pathophysiology of ventricular arrhythmias.
• Early findings suggest these agents could offer new avenues for antiarrhythmic therapy.

Conclusions:

• Novel targets involved in intracellular calcium handling present promising opportunities for developing new antiarrhythmic drugs.
• While these targets are interesting, extensive investigation into the long-term effects of associated drugs is crucial.
• Further research is required to establish the safety and efficacy of these compounds for clinical application in preventing sudden cardiac death.